Discovery of B. pseudomallei Therapeutics for Biodefense

Information

  • Research Project
  • 6690478
  • ApplicationId
    6690478
  • Core Project Number
    R43AI056644
  • Full Project Number
    1R43AI056644-01
  • Serial Number
    56644
  • FOA Number
    PAS-02-149
  • Sub Project Id
  • Project Start Date
    7/15/2003 - 20 years ago
  • Project End Date
    10/31/2003 - 20 years ago
  • Program Officer Name
    LUNDBERG, MARTHA
  • Budget Start Date
    7/15/2003 - 20 years ago
  • Budget End Date
    10/31/2003 - 20 years ago
  • Fiscal Year
    2003
  • Support Year
    1
  • Suffix
  • Award Notice Date
    7/11/2003 - 20 years ago

Discovery of B. pseudomallei Therapeutics for Biodefense

DESCRIPTION (provided by investigator): Burkholderia pseudomallei is a bioterrorist threat. With the best current therapies, lethality is typically as high as 40%. The overall goal of this application is the development of new drugs against this organism. In Phase I, we will exploit the high sequence similarity between B. pseudomallei and its less virulent relative Pseudomonas aeruginosa to build innovative screens for rapid, safe discovery of effective therapeutic agents. The two species are similar in genome size and composition, with nucleotide and amino acid sequence identities for many genes in the 50-70% range, and in their mechanisms of drug resistance. We will identify genes for new drug targets in B. pseudomallei with orthologs in P. aeruginosa, validate them as essential for survival or growth of both species, and move them into P. aeruginosa as replacements for the native orthologs. Then, we will measure the whole-genome expression profile of P. aeruginosa strains engineered to under express each B. pseudomallei target gene, and use the results to construct a validated set of sensitive whole-cell reporter screens. In Phase II, we will apply these screens to a library of over 100,000 compounds and advance the most promising candidates into lead optimization and efficacy testing in animal models.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    55743
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
    NIAID:55743\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    OSCIENT PHARMACEUTICALS CORPORATION
  • Organization Department
  • Organization DUNS
  • Organization City
    WALTHAM
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    024538443
  • Organization District
    UNITED STATES